Hypertrophic cardiomyopathy (HCM) has been considered the most common cause of sudden death (SD) in the young. However, introduction of implantable cardioverter-defibrillators (ICDs) in HCM has proved highly effective and the mainstay of preventing SD in children, adolescents, and adults by terminating malignant ventricular tachyarrhythmias. Nevertheless, ICD decision making is generally regarded as more difficult in pediatrics, and the strategy for selecting ICD patients from this population remains without consensus. Prospective studies in HCM children and adolescents have shown the American Heart Association/American College of Cardiology traditional major risk marker strategy to be reliable with >90% sensitivity in selecting patients for SD prevention. International data in >2000 young HCM patients assembled over 20 years who were stratified by major risk markers showed ICDs effectively prevented SD in 20%. Alternatively, novel quantitative risk scoring initiatives provide 5-year risk estimates that are potentially useful as adjunctive tools to facilitate discussion of prophylactic ICD risks vs benefit but are as yet unsupported by prospective outcome studies. Risk scoring strategies are characterized by reasonable discriminatory statistical power (C-statistic 0.69-0.76) for identifying patients with SD events but with relatively low sensitivity, albeit with specificity comparable with the risk marker strategy. While some reticence for obligating healthy-appearing young patients to lifelong device implants is understandable, underutilization of the ICD in high-risk children and adolescents can represent a lost opportunity for fulfilling the long-standing aspiration of SD prevention. This review provides a critical assessment of the current strengths and weaknesses of SD risk stratification strategies in young HCM patients in an effort to clarify clinical decision making in this challenging subpopulation.

Department of Cardiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Division of Cardiology Children's National Hospital Department of Pediatrics George Washington University School of Medicine Washington DC

Hypertrophic Cardiomyopathy Center Lahey Hospital and Medical Center Burlington Massachusetts

Zobrazit více v PubMed

Maron B.J., Doerer J.J., Haas T.S., Tierney D.M., Mueller F.O. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085–1092. PubMed

Marston N.A., Han L., Olivotto I., et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J. 2021;42:1988–1996. PubMed PMC

Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Eng J Med. 2000;342:365–373. PubMed

Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children. Circulation. 2007;115:773–781. PubMed

Maurizi N., Passantino S., Spaziani G., et al. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events. JAMA Cardiol. 2018;3:520–525. PubMed PMC

Balaji S., DiLorenzo M.P., Fish F.A., et al. Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm. 2019;16:1462–1467. PubMed

Lynch A., Tatangelo M., Ahuja S., et al. Risk of sudden death in patients with RASopathy hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:1035–1045. PubMed

Rowin E.J., Sridharan A., Madias C., et al. Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy. Am J Cardiol. 2020;128:75–83. PubMed

Winkler F., Dave H., Weber R., Gass M., Balmer C. Long-term outcome of epicardial implantable cardioverter-defibrillator systems in children: results justify its preference in paediatric patients. EP Europace. 2018;20:1484–1490. PubMed

Shah M.J., Silka M.J., Silva J.N.A., et al. 2021 PACES Expert Consensus Statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. J Am Coll Cardiol EP. 2021;7:1437–1472. PubMed

Silvetti M.S., Pazzano V., Verticelli L., et al. Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults? A single-centre study. EP Europace. 2018;20:1966–1973. PubMed

Maron M.S., Steiger N., Burrows A., et al. Evidence that subcutaneous implantable cardioverter-defibrillators are effective and reliable in hypertrophic cardiomyopathy. J Am Coll Cardiol EP. 2020;6:1019–1021. PubMed

von Alvensleben J.C., Dechert B., Bradley D.J., et al. Subcutaneous implantable cardioverter-defibrillators in pediatrics and congenital heart disease. J Am Coll Cardiol EP. 2020;6:1752–1761. PubMed

Rowin E.J., Burrows A., Madias C., et al. Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants. Circ Arrhythm Electrophysiol. 2020;13 PubMed

Wilkoff B.L., Fauchier L., Stiles M.K., et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2016;13:e50–e86. PubMed

Garnreiter J.M., Pilcher T.A., Etheridge S.P., Saarel E.V. Inappropriate ICD shocks in pediatrics and congenital heart disease patients: risk factors and programming strategies. Heart Rhythm. 2015;12:937–942. PubMed

Norrish G., Chubb H., Field E., et al. Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study. EP Europace. 2021;23:400–408. PubMed PMC

Lipshultz S.E., Orav E.J., Wilkinson J.D., et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;382:1889–1897. PubMed PMC

Maron B.J., Spirito P., Ackerman M.J., et al. Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1527–1535. PubMed

Maron B.J., Rowin E.J., Casey S.A., et al. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation. 2016;133:62–73. PubMed

Kaski J.P., Kammeraad J.A.E., Blom N.A., et al. Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy. Cardiol Young. 2023;22:681–698. PubMed

Lopez L., Colan S., Stylianou M., et al. Relationship of echocardiographic z scores adjusted for body surface area to age, sex, race, and ethnicity. Circ Cardiovasc Imaging. 2017;10 PubMed PMC

Lopez L., Frommelt P.C., Colan S.D., et al. Pediatric Heart Network echocardiographic Z scores: comparison with other published models. J Am Soc Echocardiogra. 2021;34:185–192. PubMed PMC

Norrish G., Ding T., Field E., et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids) JAMA Cardiol. 2019;4:918–927. PubMed PMC

Norrish G., Qu C., Field E., et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2022;29:678–686. PubMed PMC

Elliott P.M., Anastasakis A., Borger M. a., et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733–2779. PubMed

Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011:e783–e831. PubMed

Ommen S.R., Mital S., Burke M.A., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation. 2020;142:558–631. PubMed

Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–1713. PubMed

Maron M.S., Rowin E.J., Wessler B.S., et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:644–657. PubMed PMC

Maron B.J. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655–668. PubMed

Norrish G., Ding T., Field E., et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. EP Europace. 2019;21:1559–1565. PubMed PMC

Ali L.A., Marrone C., Martins D.S., et al. Prognostic factors in hypertrophic cardiomyopathy in children: an MRI based study. Int J Cardiol. 2022;364:141–147. PubMed

Petryka-Mazurkiewicz J., Ziolkowska L., Kowalczyk-Domagala M., et al. LGE for risk stratification in primary prevention in children with HCM. J Am Coll Cardiol Img. 2020;13:2684–2686. PubMed

Miron A., Lafreniere-Roula M., Steve Fan C.-P., et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142:217–229. PubMed PMC

Maron B.J., Rowin E.J., Maron M.S. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021;18:1012–1023. PubMed

Hauser R.G., Maron B.J. Lessons from the failure and recall of an implantable cardioverter-defibrillator. Circulation. 2005;112:2040–2042. PubMed

O’Mahony C., Jichi F., Ommen S.R., et al. International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) Circulation. 2018;137:1015–1023. PubMed

Zeppenfeld K., Tfelt-Hansen J., de Riva M., et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) Eur Heart J. 2022;43:3997–4126. PubMed

O’Mahony C., Jichi F., Pavlou M., et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD) Eur Heart J. 2014;35:2010–2020. PubMed

Maron B.J., Casey S.A., Olivotto I., et al. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2018;11 PubMed

Norrish G., Field E., McLeod K., et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J. 2019;40:986–993. PubMed PMC

Maron B.A., Wang R.-S., Shevtsov S., et al. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2021;12:873. PubMed PMC

Wang R.-S., Rowin E., Maron B., Maron M., Maron B. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy risk stratification. Cardiovasc Res. 2023;119:e125–e127. PubMed PMC

Zhang Q., Burrage M.K., Lukaschuk E., et al. Toward replacing late gadolinium enhancement with artificial intelligence virtual native enhancement for gadolinium-free cardiovascular magnetic resonance tissue characterization in hypertrophic cardiomyopathy. Circulation. 2021;144:589–599. PubMed PMC

Kaya E., Rassaf T., Wakili R. Subcutaneous ICD: current standards and future perspective. Int J Cardiol Heart Vasc. 2019;24 PubMed PMC

Friedli A., Burri H. S-ICDs: advantages and opportunities for improvement. Expert Rev Med Devices. 2022;19:237–245. PubMed

Maron M., Rowin E., Spirito P., Maron B.J. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2022;109:589–594. PubMed PMC

Maron B.J., Estes N.A.M., Rowin E.J., Maron M.S. Development of the implantable cardioverter-defibrillator. JACC historical breakthroughs in perspective. J Am Coll Cardiol. 2023;82:353–373. PubMed

Silka M.J., Kron J., Dunnigan A., Dick M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation. 1993;87:800–807. PubMed

Kaski J.P., Tomé Esteban M.T., Lowe M., et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart. 2007;93:372–374. PubMed PMC

Decker J.A., Rossano J.W., Smith E.O.B., et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol. 2009;54:250–254. PubMed

Kamp A.N., von Bergen N.H., Henrikson C.A., et al. Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol. 2013;34:1620–1627. PubMed

Ziółkowska L., Turska-Kmieć A., Petryka J., Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2016;37:448–458. PubMed PMC

Bharucha T., Lee K.J., Daubeney P.E.F., et al. Sudden death in childhood cardiomyopathy. J Am Coll Cardiol. 2015;65:2302–2310. PubMed

Dechert B.E., Bradley D.J., Serwer G.A., Dick M., Lapage M.J. Implantable cardioverter defibrillator outcomes in pediatric and congenital heart disease: time to system revision. Pacing Clin Electrophysiol. 2016;39:703–708. PubMed

Östman-Smith I., Sjöberg G., Rydberg A., Larsson P., Fernlund E. Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score. Open Heart. 2017;4 PubMed PMC

Ho C.Y., Day S.M., Ashley E.A., et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) Circulation. 2018;138:1387–1398. PubMed PMC

Edelson J.B., Griffis H., Burstein D.S., et al. The impact of syndromic genetic disorders on medical management and mortality in pediatric hypertrophic cardiomyopathy patients. Pediatr Cardiol. 2020;41:1180–1189. PubMed

Norrish G., Kolt G., Cervi E., et al. Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Heart Fail. 2021;8:5057–5067. PubMed PMC

Tunca Sahin G., Ozgur S., Kafali H.C., et al. Clinical characteristics of hypertrophic cardiomyopathy in children: an 8-year single center experience. Pediatr Int. 2021;63:37–45. PubMed

Alashi A., Svensson L., Klein J., et al. Characteristics and longer-term outcomes of contemporary patients <18 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 2021;140:110–117. PubMed

Norrish G., Cleary A., Field E., et al. Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1986–1997. PubMed PMC

Chan W., Yang S., Wang J., et al. Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: a multicentre retrospective cohort study. EClinicalMedicine. 2022;49 PubMed PMC

Silvetti M.S., Tamburri I., Campisi M., et al. ICD outcome in pediatric cardiomyopathies. J Cardiovasc Dev Dis. 2022;9:33. PubMed PMC